At launch, Ascendis plans to offer a suite of patient services for YORVIPATH through its U.S. Ascendis Signature Access Program (A.S.A.P.), including support navigating the treatment journey and …

Dec 19, 2024 · Reflecting this commitment, Ascendis has established a dedicated YORVIPATH team within the U.S. Ascendis Signature Access Program ® to support the patient treatment journey, …

Feb 13, 2025 · Is Yorvipath Right for Me? Your health care provider may consider treatment with Yorvipath if you have hypoparathyroidism and have been taking calcium and vitamin D treatment.

Patients who may benefit can include patients with: *Hyperphosphatemia *corrected calcium below target levels or symptomatic hypocalcemia *Hypercalcuria or nephrolithiasis despite thiazide use …

Yorvipath® is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. Conventional therapy for hypoparathyroidism consists of active vitamin …

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for YORVIPATH and any potential adverse effects on the breastfed child from …

Aug 14, 2024 · The company, through its U.S. Ascendis Signature Access Program, plans to offer patient services such as support for navigating treatment and financial assistance for eligible …

To support patients and healthcare providers, Ascendis has introduced the Yorvipath team within its U.S. Ascendis Signature Access Program. This initiative provides resources such as clinical …

Aug 13, 2024 · Yorvipath (palopegteriparatide) is a long-acting parathyroid hormone analog that releases PTH (1-34) throughout the day, which temporarily restores physiologic levels of parathyroid …

Aug 12, 2024 · At launch, Ascendis plans to offer a suite of patient services for YORVIPATH through its U.S. Ascendis Signature Access Program (A.S.A.P.), including support navigating the treatment …